Introducing misoprostol for treatment of incomplete abortion: A feasibility and acceptability study in secondary-level health facilities in Myanmar

Mary, Meighan; Tin, Khaing Nwe; Maung, Thae Maung; Maung, Hein Nyi; Ku, Saw Kler; Winikoff, Beverly

doi:10.1016/j.srhc.2023.100825

Cited by 1 publication

(1 citation statement)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Though MVA was superior to misoprostol in terms of success of complete uterine evacuation, we found the rates of complete uterine evacuation were both over 90% either after MVA or misoprostol treatment, which demonstrated that in case of limited resources settings, misoprostol could be used as an alternative of MVA on condition that post-treatment adverse events like bleeding or pain could be well managed. In a study carried out in Myanmar, the success rate of complete uterine evacuation after misoprostol intake in treating incomplete abortion was 75%, which was lower than the pooled rate of complete uterine evacuation we reported, this could be attributed to the dose, timing, and giving routes of misoprostol, and the post-abortion care provided [20] . Some experts launched studies to evaluate possible combination with misoprostol and other drugs to induce complete uterine evacuation.…”

Section: Discussioncontrasting

confidence: 77%

Comparison of misoprostol and manual vacuum aspiration in treating first-trimester incomplete miscarriage: a systematic review and meta-analysis of randomized controlled trials

Jin,

Zhang,

Yang

et al. 2023

Preprint

View full text Add to dashboard Cite

Background To provide evidence of the comparative curative efficiency and prevalence of treatment-related adverse events following manual vacuum aspiration (MVA) or misoprostol in first trimester incomplete abortion.Methods We comprehensively searched international medical literature databases, including PubMed, Medline, Ovid, Embase, and Web of science for related articles published between 2005 and 2023. After article screening, seven articles were finally included in the meta-analysis after assessment for risk of bias. Important parameters of the included studies were strictly extracted. Stata 17MP was used to compare the proportion of complete uterine evacuation, necessity for additional MVA, prevalence of adverse effects (abdominal pain, bleeding, fever, chills, nausea and vomiting), patients’ subjective evaluation and publication bias. Meta-regression was also performed.Results Seven eligible studies of 1097 patients receiving misoprostol and 1079 patients receiving MVA were included, and MVA was found to have better performance than misoprostol in terms of complete uterine evacuation (RR = 0.972, P༜0.001), regardless of age, gestational age, parity, dosage of misoprostol, and marital status. Meanwhile, misoprostol was related to higher possibility for additional MVA (RR = 7.112, P༜0.001). In terms of adverse events, misoprostol medication led to more frequent bleeding (RR = 1.91, P༜0.001), chills (RR = 7.5, P = 0.018), fever (RR = 4.34, P = 0.001), nausea (RR = 3.13, P = 0.005), and vomiting (2.21, P = 0.008).Conclusion MVA outperformed misoprostol in terms of accomplishing complete uterine evacuation in patients with first-trimester incomplete miscarriage. Moreover, the occurrence rate of adverse events was lower in MVA group than that in misoprostol group. However, since the rate of complete uterine evacuation after MVA and misoprostol were both over 90%, misoprostol was also considered as an alternative for MVA in limited resources settings.Trial registration: The research was formally registered on International Platform of Registered Systematic Review and Meta-analysis Protocols (registration number: INPLASY202350113) before statistical analysis.

show abstract

Section: Discussioncontrasting

confidence: 77%